The UK Government has announced that every newborn baby in England will have their genetic code mapped to test for a wide range of conditions, part of a plan that will also see £650m invested in DNA research by 2030. 

The Department for Health and Social Care said that genomics and AI would be used to “revolutionise prevention” and provide faster diagnoses and an “early warning signal for disease”. 

Health Secretary Wes Streeting said in a statement: “With the power of this new technology, patients will be able to receive personalised healthcare to prevent ill-health before symptoms begin, reducing the pressure on NHS services and helping people live longer, healthier lives.” 

The NHS began a study in October last year to look for genetic disorders that develop in early childhood, but was limited to testing for those which have effective treatments. 

A BBC report said funding for the new initiative will also support efforts by Genomics England to build one of the world’s largest research databases, with the goal of containing over 500,000 genomes by 2030. 

Biotech for rare diseases

Oxford-based rare disease biotech, SynaptixBio, has welcomed the announcement but says it must soon be followed up by a detailed implementation plan. 

Dan Williams, CEO at SynaptixBio, said: “Rare diseases are primarily genetic in origin, indeed most are the result of single gene mutations. Unfortunately, most are currently untreatable, so identifying them shortly after birth maximises the opportunities to develop personalised care plans and access appropriate support, which can be life-changing for those affected and their families.” 

SynaptixBio was founded just four years ago to develop a therapy for H-ABC, the most severe form of TUBB4A leukodystrophy, a debilitating and life-limiting degenerative neurological disorder. 

The company recently announced it had selected its candidate drug for taking into clinical trials. 

SynaptixBio was awarded a £2 million BioMedical Catalyst grant from Innovate UK to support first-in-human clinical trials of its therapeutic targeting H-ABC, which affects mainly babies and young children. 

This followed an earlier grant, in November 2023, from Innovate UK to expand SynaptixBio’s search for rare disease therapies. 

Dan Williams added: “Identifying a candidate drug is incredibly important. It means the drug has passed toxicity tests and is stable. We are looking forward to getting into the clinic, though trials in the rare disease space are a lot harder to design due to the limited number of patients.” 

SynaptixBio is using a form of gene silencing technology, called antisense oligonucleotides, to stop a genetic mutation from going on to create toxic proteins. 

The technology has been proven in the treatment of certain dystrophies, including Duchenne muscular dystrophy, and is currently under trial by University College London Hospitals as a potential therapy for Alzheimer’s disease.

Diana Spencer, Senior Digital Content Editor, DDW